| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/04/2002 | WO2001070205A3 Composition comprising paracetamol and niflumic acid |
| 04/04/2002 | WO2001068837A3 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 04/04/2002 | WO2001068102A3 Nystatin formulation having reduced toxicity |
| 04/04/2002 | WO2001066741A3 Kcnb: a novel potassium channel protein |
| 04/04/2002 | WO2001066098A3 Therapeutic uses of ppar mediators |
| 04/04/2002 | WO2001064643A3 Benzamides and related inhibitors of factor xa |
| 04/04/2002 | WO2001062792A3 Cancer treatment and prognosis involving hes-1 protein |
| 04/04/2002 | WO2001062260A3 Improvement of implantation rate |
| 04/04/2002 | WO2001060375A3 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration |
| 04/04/2002 | WO2001060350A3 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| 04/04/2002 | WO2001056557A3 Compositions useful as inhibitors of erk |
| 04/04/2002 | WO2001049298A3 Novel therapeutic use of enoxaparin |
| 04/04/2002 | WO2001049282A3 Therapeutic preparations of highly unsaturated fatty acids |
| 04/04/2002 | WO2001048231A3 Method of achieving persistent transgene expression |
| 04/04/2002 | WO2001047898A3 Substituted piperazine derivatives and their use as inhibitors of the microsomal triglyceride transfer protein (mtp) |
| 04/04/2002 | WO2001047522A3 Association of deoxyfructosazine and an antidiabetic of the biguanide family |
| 04/04/2002 | WO2001047507A3 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 04/04/2002 | WO2001044197A3 2-phenyl-quinoline derivatives and their use as contracting agent for smooth muscles |
| 04/04/2002 | WO2001039720A3 Dna polymerase inhibitors, mikanolide and dihydromikanolide |
| 04/04/2002 | WO2001034802A3 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 04/04/2002 | WO2001032219A3 Treatment of c. difficile toxin b associated conditions |
| 04/04/2002 | WO2000072021A3 Cancer associated antigens and uses therefor |
| 04/04/2002 | WO2000070099A3 Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| 04/04/2002 | WO2000064454A9 Pharmaceutical composition comprising an inositol and a metal ion for improving insulin sensitivity and glucose metabolism |
| 04/04/2002 | WO2000063193A9 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| 04/04/2002 | WO2000053224A3 Use of inhibitors of endotoxin for the treatment of heart failure and of cachexia |
| 04/04/2002 | WO2000048549A3 Anticonvulsant derivatives useful in treating essential tremor |
| 04/04/2002 | US20020040203 Method for transdermal or intradermal delivery of molecules |
| 04/04/2002 | US20020040164 For use in anxiolytic agents |
| 04/04/2002 | US20020040162 Contrast media for angiography |
| 04/04/2002 | US20020040155 Radiosensitizing taxanes and their pharmaceutical preparations |
| 04/04/2002 | US20020040154 Reacting arylhydroxy compound and an epoxy compound to form an epoxy-aryl ether; reacting epoxy-aryl ether with active methylene compound to form a lactone; reducing to provide hydroxy-substituted tetrahydrofuran |
| 04/04/2002 | US20020040153 Reductive hydrolysis of 5-(amido)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)1,3-dihy -droisobenzofuran to form 5-formyl-derivative; converting to citalopram |
| 04/04/2002 | US20020040150 Skin treatment compositons containing a cationic polymer and a microparticle or nanoparticle vector |
| 04/04/2002 | US20020040149 EP4 receptor selective agonists in the treatment of osteoporosis |
| 04/04/2002 | US20020040148 Diphenyl heterocyclic thioamide derivatives |
| 04/04/2002 | US20020040147 Novel catechols as antimicrobial agents |
| 04/04/2002 | US20020040146 Useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in therapy of disease states associated with vasoconstriction |
| 04/04/2002 | US20020040140 Crystalline therapeutic agent |
| 04/04/2002 | US20020040139 Intranasal formulations for treating sexual disorders |
| 04/04/2002 | US20020040136 Vitronectin receptor antagonist |
| 04/04/2002 | US20020040135 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them |
| 04/04/2002 | US20020040128 Carbohydrate-blood protein complex for us as an oxygen transporter |
| 04/04/2002 | US20020040064 Administering agent that inhibits the contraction or migration of smooth muscle cells; sustained dosage; biological stents |
| 04/04/2002 | US20020040063 Liquid formulation of metformin |
| 04/04/2002 | US20020040062 For upregulation of expression of a cell antigen without inducing shedding of said antigen from the cell |
| 04/04/2002 | US20020040060 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor |
| 04/04/2002 | US20020040059 Controlling cancer by reducing its growth and improving response to therapy |
| 04/04/2002 | US20020040058 Oral administration of a preparation having a) long chain polyunsaturated fatty acids, and b) specified phospholipids, and c) compounds that factor in methionine metabolism, such as folate, B vitamins, magnesium and zinc |
| 04/04/2002 | US20020040056 Oxa acids and related compounds for treating skin conditions |
| 04/04/2002 | US20020040054 Comprehensive pharmacologic therapy for treatment of obesity |
| 04/04/2002 | US20020040053 Administering 2,5,7,8-tetramethyl-2-( beta-carboxyethyl)-6-hydroxychromane, or 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychromane; treating arteriosclerosis, disease caused by oxidated low density lipoprotein |
| 04/04/2002 | US20020040052 By administering a poyalkoxyflavonoid having a specific structure, especially nobiletin or tangeretin; plant extract from citrus family |
| 04/04/2002 | US20020040051 Solid dispersion of ipriflavone for oral administration and its manufacturing methods |
| 04/04/2002 | US20020040050 Immunosuppressive agents |
| 04/04/2002 | US20020040049 Administrating to a mammal a gastrointestinal lipase inhibitor, such as orlistat; reducing intensity of fullness, nausea, bloating or gastric distress following ingestion of fat rich meals or foods |
| 04/04/2002 | US20020040048 (2S,4R)-4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carboxylic acid N'-isobutyl-N'-(4-methyl-benzenesulfonyl)-hydrazide, for example; inhibitors of metalloproteases, e.g. zinc proteases; vasodilators |
| 04/04/2002 | US20020040047 Novel Use |
| 04/04/2002 | US20020040046 Dissolved or dispersed in at least one oil with one or more emulsifiers, capapble of forming an emulsion upon dilution with an aqueous phase; bioavailability; drug such as fenofibrate, pravastatin, and atorvastatin |
| 04/04/2002 | US20020040045 Method of treating isolated systolic hypertension |
| 04/04/2002 | US20020040043 Amidino derivatives and their use as thrombin inhibitors |
| 04/04/2002 | US20020040042 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| 04/04/2002 | US20020040041 Single dosage form of reboxetine and pindolol; treating depression, panic disorders, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorder, addictive disorders, social phobia |
| 04/04/2002 | US20020040040 N-(3,5-bis-trifluoromethyl-benzyl)-6-(4-hydroxyacetyl-piperazin-1 -yl)-N-methyl-4-o-tolyl-nicotinamide, for example |
| 04/04/2002 | US20020040039 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 04/04/2002 | US20020040038 Administering donepezil or its hydrochloride salt |
| 04/04/2002 | US20020040037 Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol |
| 04/04/2002 | US20020040036 1-(4-bromophenyl)-2-(1-methyl-2-piperidinyl)-1-ethanone, for example; treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Korsakoff's disease and frontal lobe and subcortical dementias |
| 04/04/2002 | US20020040035 Quinuclidine-substituted aryl compounds for treatment of disease |
| 04/04/2002 | US20020040034 Administering to a human for treating allergic asthma while avoiding adverse side-effects associted with adminstration of nonsedating antihistamines, a descarboethoxyloratadine and a leukotriene inhibitor(a decongestant) |
| 04/04/2002 | US20020040033 Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients |
| 04/04/2002 | US20020040032 Methods for stimulation of synthesis of synaptophysin in the central nervous system |
| 04/04/2002 | US20020040028 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia |
| 04/04/2002 | US20020040027 Method for the prevention of the reinfestation of warm-blooded animals by ectoparasites |
| 04/04/2002 | US20020040026 Phenyloxy-and phenylthiosubstituted pyrimidines and triazines and derivatives useful for treating anxiety, depression, effective disorders, post-traumatic stress disorders etc. |
| 04/04/2002 | US20020040025 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 04/04/2002 | US20020040024 A phenoxy substituted piperidine derivative, useful for treating or preventing histamine H3 receptor activity |
| 04/04/2002 | US20020040022 Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection |
| 04/04/2002 | US20020040021 Method for treating sexual dysfunction |
| 04/04/2002 | US20020040020 Substituted pyrazoles |
| 04/04/2002 | US20020040019 Substituted pyrazoles |
| 04/04/2002 | US20020040018 Subtype selective melatonergics |
| 04/04/2002 | US20020040017 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 04/04/2002 | US20020040016 Derivatives of azetidine and pyrrolidine |
| 04/04/2002 | US20020040015 Administering to the mammal an anti-angiogenesis factor and a photosensitizer to permit to localize in the chorodial neovasculature, irradiating the chorodial neovasculature with laser light |
| 04/04/2002 | US20020040014 Novel aryl fructose-1,6-Bisphosphatase inhibitors |
| 04/04/2002 | US20020040013 Novel therapeutic use of low molecular weight heparins |
| 04/04/2002 | US20020040012 A synthetic pentasaccharide which is a selective inhibitor of faxtor xa, acting via antithrombin III |
| 04/04/2002 | US20020040011 Naphthoquinone compositions and uses thereof |
| 04/04/2002 | US20020040008 Administering agent for inhibiting interaction between P-selectin and a ligand of P-selectin |
| 04/04/2002 | US20020040007 Novel macrolide antibiotics |
| 04/04/2002 | US20020040006 Topically applying onto skin ascorbic acid in mixture with at least one monosaccharide ester of ascorbic acid and/or at least one metal salt of phosphorylated ascorbic acid |
| 04/04/2002 | US20020040005 Comprising tannic acid or tannin complexes from the sap of a plant of the Musaceas Family and a pharmaceutically acceptable carrier |
| 04/04/2002 | US20020040003 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus |
| 04/04/2002 | US20020040002 Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
| 04/04/2002 | US20020040000 Human kcnq5 potassium channel, methods and compositions thereof |
| 04/04/2002 | US20020039998 Administering to human therapeutically effective amount of a combination of drug which is metabolized by cytochrome p450 monooxygenase or pharmaceutically acceptable salt thereof and ritonavir |
| 04/04/2002 | US20020039997 Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
| 04/04/2002 | US20020039993 Use of inhibitors of the activation of CXCR4 receptor by SDF-1 in treating rheumatoid arthritis |
| 04/04/2002 | US20020039790 Adjustment of immunology of cells |